Introduction
Müllerian inhibiting substance (MIS, also known as anti-Müllerian hormone or AMH) is produced by the Sertoli cells of the fetal testes shortly after commitment of the indifferent primordial gonads to testicular differentiation under the influence of the transcription factor, SRY, the sex-determining region on the Y chromosome (1) . The signal activity of MIS in male embryos is to cause regression of the Müllerian ducts (or paramesonephric ducts), which are the anlagen of the female reproductive tract present in the bipotential urogenital ridges. In females, the Müllerian ducts differentiate into the fallopian tubes, uterus, cervix and anterior portion of the vagina in the absence of MIS. In males, the absence of MIS or its type II receptor (MISR2 or AMHR2) leads to development of a congenital, autosomal recessive disorder, persistent Müllerian duct syndrome (2), a rare form of pseudohermaphroditism with Müllerian duct remnants that can interfere with testicular descent (3) .
Both MIS and MISR2 are expressed in the granulosa and Sertoli cells of postnatal gonads. In males, MIS continues to be expressed specifically in Sertoli cells at high levels postnatally, well after Müllerian duct regression, through puberty, after which its expression is much lower but still measurable in serum (4) . A postnatal role for MIS has been difficult to discern, particularly since spermatogenesis in mice with deletion of MIS or MISR2 appears normal, despite displaying Leydig cell hyperplasia, suggesting the MIS does not have any deleterious effect on testicular function or development (5, 6) . In contrast, females begin to express low levels of MIS specifically in granulosa cells of preantral follicles with the onset of folliculogenesis after birth (7, 8) . The absence of MIS signaling in females does lead to premature ovarian failure (9) and MIS has been shown to block the growth of primary follicles (10, 11) . The molecular mechanisms underlying any of these postnatal phenotypes have yet to be reported. In addition, MISR2 expression has been detected in the ovarian surface epithelium (12) , in the myometrium (13) and in motor neurons (14) ; roles for MIS signaling in those settings are currently being investigated.
Deletion of MIS, when combined with deletion of the gene for the inhibin tumor suppressor, leads to more aggressive testicular tumorigenesis of the somatic cells than inhibin deletion alone (15) , suggesting that MIS signaling might synergize with inhibin to suppress tumorigenesis or tumor progression. The putative tumor suppressor activity of MIS has been studied mostly in epithelial ovarian cancer, the histology of which resembles that of the Müllerian duct-derived fallopian tube (serous), uterus (endometrioid) and cervix (mucinous ) (16) , which like the fetal Müllerian ducts can express MISR2 and in some cases have been shown to be inhibited by MIS (17) . The inhibition of ovarian cancer cell proliferation by MIS has been shown by two non-exclusive mechanisms that rely on upregulation of the cyclin-dependent inhibitor, p16 (18) , and by preferentially affecting the cancer stem cell population (19) . In the cancer stem cell studies, SMAD1/5/8 (Sma and mothers against decapentaplegic-related homolog) phosphorylation, the canonical downstream signaling mechanism involved in Müllerian duct regression (20) , was observed with addition of MIS (19) .
We are studying β-catenin biology in the context of gonadal and reproductive tract development and pathogenesis. Dysregulated activation of β-catenin is associated with tumorigenesis in many settings (21) , including reproductive tract tissues and gonads (22) (23) (24) (25) (26) (27) . β-Catenin is a mediator of the wingless-related MMTV integration site (WNT) family of secreted proteins involved in regulating a variety of developmental processes (21) , including the reproductive tracts of male and female mice (13, 28) . WNTs bind to their respective cell surface frizzled/lrp receptors and induce signal transduction through three known and very different mechanisms: through the canonical WNT/β-catenin pathway, through the non-canonical WNT/Ca 2+ pathway and by controlling cellular polarity. β-Catenin is normally found in the cytoplasm of cells, often coupled to adherens junctions (29) and its stability is regulated by a destruction complex formed by axin, adenomatous polyposis complex, casein kinase 1 and glycogen synthase kinase-3β that phosphorylates β-catenin at its N-terminus and leads to its ubiquitination and proteolytic degradation. During canonical WNT signaling, β-catenin escapes this complex, accumulates in the cytoplasm, and translocates to the nucleus to activate the transcription of various target genes as a cofactor bound to members of the T-cell factor (TCF)/lymphoid enhancer factor (LEF) transcription factor family (21).
Although constitutive activation of β-catenin specifically in somatic cells of murine testes using Misr2-driven Cre recombinase to delete exon 3 of a flox allele of β-catenin (Cre/+;Ctnnb1
Δ(ex3)/+
) has been shown to cause premature germ cell loss and defective spermatogenesis, it does not appear to induce tumorigenesis in testes (30, 31) . When combined with deletion of other tumor suppressors, such as phosphatase and tensin homolog (PTEN), somatic testicular tumors are evident within a few weeks after birth. Sertoli cells in Cre/+;Ctnnb1 Δ(ex3)/+ testes continue to proliferate and express higher levels of MIS, but no proliferation and very low expression of MIS was observed in control Sertoli cells (30, 31) . We hypothesized that the lack of testicular somatic cell carcinogenesis is because of the high levels of MIS expression, acting as a potent tumor suppressor in this setting, and that loss of MIS signaling in the Ctnnb1 Δ(ex3)/+ mice would result in testicular carcinogenesis. In this study, we show that deletion of both alleles of Misr2 in Ctnnb1 Δ(ex3)/+ mice results in testicular tumorigenesis with 100% penetrance within a few months postnatal. Analyses of the tumors indicate they are sex cord-stromal tumors generally composed of both Sertoli and Leydig cells and are relatively devoid of nuclear phosphorylated-SMAD1/5/8, which is the canonical downstream signaling mechanism induced by MIS binding to its receptor. These studies show that endogenous MIS signaling alone can silence the oncogenic activity of β-catenin to induce tumorigenesis.
Materials and methods

Mouse genetics and husbandry
Mice used in this study were housed under standard animal housing conditions and maintained on a C57BL/6;129/SvEv mixed genetic background. tm1Sor (Jackson Labs) mice. Tail biopsies were used for the genotyping of mice as described previously (31, 34, 35) . Gross photos were taken using a Nikon SMZ1500 microscope with an attached Spot Digital camera (Diagnostic Instruments, Sterling Heights, MI) or a Nikon D60 digital camera with a macro lens.
Histology, immunohistochemistry and immunofluorescence analyses
Murine testes were collected at different stages of development and fixed overnight at 4°C in 4% paraformaldehyde for immunofluorescence/immunohistochemistry (IF/IHC) or Bouin's solution for histology. IF/IHC protocols used in this study are described previously (31, 36) . The following primary and secondary antibodies were used in this study: β-catenin (BD Transduction Laboratories, San Jose, CA), E-cadherin, AMH/MIS, proliferating cell nuclear antigen (PCNA), vimentin, platelet-derived growth factor receptor-α (PDGFRα), Wilms' tumor (WT1), 3β-hydroxysteroid dehydrogenase (3βHSD1), cytochrome P450 17-hydroxylase/20 lyase (CYP17A1), leukemia inhibitory factor receptor (LIFR), p21 and cyclin D2 were from Santa Cruz Biotechnology, Santa Cruz, CA; TCF1, LEF1, PTEN, p15, phosphorylated Sma and mothers against decapentaplegic-related homolog 1/5/8 (pSMAD1/5/8, SMAD2/3 and SMAD1/5/8 (Cell Signaling Technology, Danvers, MA); germ cell nuclear antigen (GCNA, a gift from Dr George Enders) (37); SRY (sex-determining region Y)-box 9 (SOX9), pSMAD2 (Millipore, Billerica, MA); Nestin, β-galactosidase (Abcam, Cambridge, MA); KIT proto-oncogene (cKIT, R&D systems, Minneapolis, MN), α−smooth muscle actin (αSMA; Sigma, St Louis, MO), cyclin D1 (Neomarkers, Kalamazoo, MI), anti-steroidogenic factor 1 (SF1, a gift from Dr Ken-ichirou Morohashi). AlexaFluor second antibodies (Invitrogen, Carlsbad, CA); biotinylated donkey anti-mouse or anti-rabbit or anti-goat antibody F(ab) 2 (Jackson ImmunoResearch Laboratories, West Grove, PA). Photographs were taken with either a Nikon TE2000S with an attached Spot camera or a Nikon Eclipse Ni fitted with Nikon DSF12/DS-Q1MC camera.
β-Galactosidase staining
Testes were collected from 5-week-old Cre;LacZ and LacZ flox/+ control mice, fixed in 4% paraformaldehyde at 4°C for 1 h, washed in rinse buffer and stained with X-Gal solution as described (34) .
Results
Loss of MISR2 permits dysregulated β-catenin signaling to induce testicular tumorigenesis
To confirm faithful expression of Misr2-Cre in testes, we mated Misr2-Cre mice with flox Rosa26-LacZ reporter mice. β-Galactosidase activity was limited to the Sertoli and interstitial cells of Cre/+;LacZ testes ( Figure 1A -C) as observed previously (30, 31, 34, 36) . Expression of a conditionally activated allele of β-catenin in Sertoli cells leads to continued proliferation of Sertoli and expression of glial cell-derived nuclear factor and MIS, all of which are indicative of Sertoli cell immaturity, but not to tumorigenesis (30, 31, 38) . To test whether loss of MIS signaling in Cre/+;Ctnnb1 Δ(ex3)/+ testes affects the oncogenic potential of dysregulated β-catenin, we developed two more mouse models in which both Misr2 alleles are deleted by mating Cre/+;Ctnnb1 
Deletion of MIS signaling combined with activated β-catenin results in sex cord-stromal tumor development
Normal germ cell development and spermatogenesis in Mis and Misr2 knockout mice was reported previously (5, 6) . Some of the older Mis and Misr2 mutant mice show Leydig cell hyperplasia and focal seminiferous degeneration. However, testicular tumorigenesis was only reported in one mouse. Similar to these observations, normal spermatogenesis and no tumorigenesis were observed in 4-week-old Cre/Cre or Cre/LacZ testes ( and 2T) or a less differentiated morphology ( Figure 2U and 2V) , the mix of which are a hallmark of Sertoli/Leydig cell tumors (40) . Figure 2A and Figure 2C , available at Carcinogenesis Online). To investigate whether loss of MIS signaling and activation of β-catenin signaling synergize in the development of the germ cell loss phenotype, we examined the expression of the germ cell marker, GCNA (37) Figure 3A and 3B), none were observed in 7-week-old Cre/Cre;Ctnnb 1Δ(ex3)/+ mice testes ( Figure 3C ), suggesting that Sertoli cells with loss of MIS signaling and activation of canonical WNT signaling loose their capacity to support spermatogenesis much earlier than mice with alterations in either MIS or WNT/β-catenin signaling alone. MISR2-Cre is expressed in both Sertoli and interstitial Leydig cells (Figure 1) , and tumors formed in Cre/LacZ;Ctnnb1 Δ(ex3)/+ also express β-galactosidase (Supplementary Figure 1H , available at Carcinogenesis Online), indicating that Cre/Cre;Ctnnb1 Δ(ex3)/+ tumors are derived from either Sertoli or interstitial Leydig cells. We examined specific markers for these cell types to characterize the tumors formed in these mutant testes. Expression of SOX9, a Sertoli cell marker (41), was absent in tumors ( Figure 3F) ; this was expected because we observed nuclear accumulation of β-catenin suggestive of activated WNT/β−catenin signaling in these tumors ( Figure 1 ) and WNT/β− catenin signaling is known to suppress the expression of SOX9 in mouse testes (42) . Consistent with a previous report (31) Figure 3E and 3F) , and a normal arrangement of SOX9-positive cells was observed in Cre/Cre, Misr2-deleted mice ( Figure 3D ). Examination of two other Sertoli 
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cell-specific markers, WT1 (43) 
Altered expression of downstream targets of MIS/MISR2 in Cre/ Cre;Ctnnb1
Δ(ex3)/+ tumors SMAD1/5/8 are the downstream targets of MIS signaling (1, 20, 51) and are widely expressed in testes including Sertoli cells (52) . Deletion of SMAD1/5/8 in mouse gonads causes development of stromal tumors indicating their importance in gonadal tumor suppression (53) . Deletion of MIS and MISR2 in mice causes Leydig hyperplasia (5,6), as does activation of β-catenin in somatic cells of the testis using MISR2-Cre (30, 31 Figure 5A and 5B). Germ cells in the Cre/Cre;Ctnnb1 Δ(ex3)/+ testes are completely lost by this stage (Figure 3) Figure 4A and B, available at Carcinogenesis Online), suggesting that neither MIS signaling is required for its expression nor does dysregulated WNT/β-catenin signaling affect its expression. However, since few Cre/Cre;Ctnnb1
tumor cells expressed p27 kip1 in (Supplementary Figure 4C and D, available at Carcinogenesis Online), it appears that TGFβ signaling is no longer able to induce its expression in this setting. Expression analyses of p15, p21 and cyclin D2, other targets of TGFβ signaling, showed similar results in support of that interpretation (Supplementary Figure 4E -P, available at Carcinogenesis Online).
Cre/Cre;Ctnnb1
Δ(ex3)/+ tumors have high levels of chromosomal instability TCF1, LEF1 and cyclin D1 are well-known targets of canonical WNT/β-catenin signaling (24) and their expression was high in Cre/ Cre;Ctnnb1 Δ(ex3)/+ tumors ( Figure 6A-I) , confirming upregulated nuclear β-catenin activity. We have shown previously that dysregulated activation of WNT/β-catenin signaling induces development of slow growing ovarian endometrioid adenocarcinoma tumors in mice and that the TP53 senescence pathway could be responsible for their indolence (24) . It was only with concomitant deletion of PTEN, accompanied by suppression of TP53 expression in those tumors that allowed them to grow and become malignant. We did not detect a difference in either TP53 expression ( Figure 6N-Q deletion in our previous ovarian cancer model, TP53 expression appears to be uniformly high in the tumors (Figure 6N-Q) .
The loss of MISR2 tumor suppressor activity resembles the loss of PTEN Either activation of Kras or deletion of Pten in mice with dysregulated WNT/β-catenin signaling also permits development of testicular stromal tumors with similar molecular and histological characteristics (38, 54) . We showed above that, similar to Pten loss or Kras activation, loss of MIS signaling, which was upregulated with activation of β-catenin (30, 31) , is also sufficient to initiate carcinogenesis in mice with dysregulated WNT/β-catenin signaling. Similar to Cre/Cre;Ctnnb1 5 ). These studies indicate that the loss of MIS signaling permits dysregulated β-catenin signaling to initiate testicular tumorigenesis with characteristics similar to the loss of the PTEN tumor suppressor.
Discussion
Tumor suppressor activity for MIS signaling was first hypothesized largely on the basis of its ability to cause regression of the fetal Müllerian ducts and the remarkable similarity of epithelial ovarian cancer histology to the Müllerian duct-derived female reproductive tract tissues (1, 55) . Since then several reports have shown that the MIS ligand can inhibit the growth of ovarian cancer cells in vitro and in vivo using xenotransplant models (56, 57) , and the therapeutic potential of MIS appears to require expression of MISR2 (58, 59) . Other cancer types where MISR2 has also been detected, including breast cancer, prostate and endometrial, have been shown to respond to MIS treatment as well (60) (61) (62) . In this study, we have shown that the endogenous expression of MIS in Sertoli cells can also inhibit tumorigenesis by dysregulated WNT/β-catenin signaling and that deleting its receptor, MISR2, completely abolishes that activity and leads to Sertoli/Leydig cell tumor development within the first 5 weeks postnatal with 100% penetrance. This situation is similar to that observed with homozygous deletion of Pten, which alone does not induce tumorigenesis, at least it does not do so efficiently. It is only when Pten deletion is combined with deletion of another tumor suppressor or activation of an oncogene that tumorigenesis occurs with rapid onset. Additionally, the expression of MIS is induced by dysregulated WNT/β-catenin signaling (30, 31) , which might be a feedback mechanism for tumor suppression in this setting. It would be interesting to determine whether lower, more physiological levels of MIS production in the adult testes would be sufficient to inhibit tumorigenesis or whether the induced higher levels are required.
The actual molecular mechanisms involved in MIS-mediated tumor suppression in the Cre/+;Ctnnb1 Δ(Ex3)/+ mice are not entirely known. The canonical MIS signaling cascade involves binding of the MIS ligand to MISR2 and activation of its latent kinase activity; phosphorylation and activation of the MIS type 1 receptor kinase, which can be either ACVR1 or BMPR1A, depending on the setting (20, 32, 63) , to induce its kinase activity; and subsequent phosphorylation of SMAD1/5/8 and translocation into the nucleus in a complex with SMAD4 to regulate the expression of target genes. We showed that pSMAD1/5/8 levels were reduced in the Cre/Cre;Ctnnb1 Δ(Ex3)/+ tumors ( Figure 5 ) indicating the absence of MIS signaling. These results also suggested that the BMP signaling pathway, which like MIS requires SMAD1/5/8 phosphorylation, is not operative in these tumors. Phosphorylation of SMAD2/3 appeared to be very abundant in the Cre/Cre;Ctnnb1 Δ(Ex3)/+ tumors, which could be the result of either dysregulated WNT/β-catenin signaling or by deletion of MIS signaling. The latter hypothesis seems less probable since we readily observed both pSMAD1/5/8 and pSMAD2 in tumorlets from younger mice (Supplementary Figure 2 , available at Carcinogenesis Online). The importance of pathological changes in the TGFβ signaling pathway in carcinogenesis, both pro-oncogenic and suppressive, has been well described (64) , but a role for the activin signaling pathway has yet to be firmly established. However, mice that are deficient in the activin antagonist, inhibin, develop ovarian and testicular sex chord-stromal tumors (65) and do so with even more intensity when accompanied by MIS deletion (15) . Thus, the contribution of the high levels of pSMAD2/3 in the testicular tumors in the Cre/ Cre;Ctnnb1 Δ(Ex3)/+ mice could play an important role in tumorigenesis but that role is probably independent of MIS signaling.
Fewer than 10% of testicular tumors are sex cord-stromal tumors, the majority of which are either Leydig or Sertoli cell tumors (40) . On the other hand, mixed Sertoli/Leydig cell tumors are exceptionally rare in human testes. Many of the tumor sections from Cre/Cre;Ctnnb1 Δ(Ex3)/+ mice had characteristics of both Sertoli/Leydig cell tumors but that is probably a result of lesions from the two cell types merging over time.
No mixing of tumor cell types was ever observed in these tumors. In the Cre/Cre;Ctnnb1 Δ(Ex3)/+ mice the oncogenic trigger, dysregulated WNT/β-catenin signaling, is active in practically every Sertoli and Leydig cell, which could account for both the number of lesions and their Sertoli and Leydig cell characteristics but this would not normally be the case in humans. There are numerous reports of human persistent Müllerian duct syndrome patients who also presented with intra-abdominal testicular tumors (66) , suggesting that, as with Cre/ Cre;Ctnnb1 Δ(Ex3)/+ mice, the loss of MIS signaling in these patients might be a factor in tumorigenesis. The cryptorchid testes of persistent Müllerian duct syndrome patients, like all cryptorchid testes, are usually surgically placed in the scrotum at infancy upon discovery because of the otherwise high association with testicular tumorigenesis (67, 68) . Thus, an association linking the absence of MIS signaling directly with testicular tumorigenesis has been difficult to assess. Unlike humans, testicular descent is normal in mice with either Mis or Misr2 deletion (5,6), removing it as a confounding factor in the Cre/Cre;Ctnnb1 Δ(Ex3)/+ mice and directly implicating MIS signaling as a tumor suppressor.
The discovery that endogenous MIS is a tumor suppressor raises some physiologically important issues that will need to be addressed. For example, MISR2 is expressed in the ovarian surface epithelium and the contribution of disrupted MIS signaling to epithelial ovarian cancer tumorigenesis will need to be investigated. We would like to determine whether activating the canonical MIS signaling pathway with either SMAD1/5/8 phosphorylation or the other reported mechanisms (1) downstream of MISR2 rescues the tumorigenic phenotype in the Misr2-delete mice. Most gynecological cancers develop after menopause, when serum MIS levels have dropped to very low or undetectable levels (69), potentially abrogating the tumor suppressor effects of MIS in these patients. Additionally, preclinical studies using xenotransplants and MIS therapy to inhibit tumor progression needs to be done to strengthen the case for offer this promising therapeutic mechanism to treat these patients (1, (55) (56) (57) . Our results here support the rationale for MIS therapy to treat gynecological cancer patients with the expectation that MIS signaling and its tumor suppressor activity can be reactivated in those tumors that still express MISR2.
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